THE ROLE OF ESTROGEN AND ANDROGEN DEFICIENCY IN THE DEVELOPMENT AND PROGRESSION OF DRY EYE DISEASE

Authors

  • Murodov Murodjon Saidjon o‘g‘li Assistant, Central Asian Medical University ORCID: 0009-0004-0287-6601
  • Nazirdjonov Murodiljon Abdusaitovich Assistant, Central Asian Medical University ORCID: 0009-0001-1702-9577
  • Asqaraliyev A’zamjon Axadjon o‘g‘li Clinical Resident, Central Asian Medical University ORCID: 0009-0007-6086-1063

Keywords:

dry eye disease; estrogen; androgen; sex hormones; meibomian gland dysfunction; tear film; ocular surface; inflammation; menopause; Sjögren disease.

Abstract

Background: Dry eye disease (DED) is a multifactorial disorder involving loss of tear-film and ocular-surface homeostasis. Sex hormones influence several ocular-surface tissues, including the lacrimal and meibomian glands, corneal epithelium and conjunctiva. Hormonal changes may therefore modify susceptibility to both aqueous-deficient and evaporative forms of DED.

Objective: To review current evidence on the biological and clinical relationships between estrogen and androgen signaling and the development and progression of DED, with particular attention to meibomian gland function, tear-film stability and ocular-surface inflammation.

Methods: This narrative review synthesizes the source manuscript and selected peer-reviewed literature, including the TFOS DEWS III reports published in 2025, earlier TFOS consensus reports and clinical epidemiological evidence. The available evidence was critically compared and organized by hormonal pathway and clinical relevance. No original patient data or experimental measurements were generated.

Results: Androgens contribute to the regulation of meibomian and lacrimal gland physiology and ocular-surface immune activity. Reduced androgen signaling has been associated with impaired glandular function and may contribute to both evaporative and aqueous-deficient DED. Estrogen effects are more complex and depend on tissue, concentration, receptor context and hormonal environment. Observational evidence has linked postmenopausal hormone therapy, particularly estrogen-only therapy, with a higher prevalence of dry-eye symptoms or diagnosis; these findings do not establish causality. Hormonal influences interact with aging, autoimmune disease, medication exposure, environmental conditions and inflammatory pathways.

Conclusion: Sex-hormone signaling is an important component of ocular-surface biology but should not be considered an isolated cause of DED. Clinical assessment should identify the dominant disease subtype and relevant systemic factors. Hormone therapy should not be initiated solely to treat DED without an independent medical indication and specialist assessment. Further prospective and mechanistic studies are required.

 

 

References

1.Wolffsohn JS, Benítez-Del-Castillo JM, Loya-Garcia D, et al. TFOS DEWS III: Diagnostic Methodology. American Journal of Ophthalmology. 2025;279:387–450. doi:10.1016/j.ajo.2025.05.033.

2.Stapleton F, Argüeso P, Asbell P, et al. TFOS DEWS III: Digest. American Journal of Ophthalmology. 2025;279:451–553. doi:10.1016/j.ajo.2025.05.040.

3.Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III: Management and Therapy. American Journal of Ophthalmology. 2025;279:289–386. doi:10.1016/j.ajo.2025.05.039.

4.Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286(17):2114–2119. doi:10.1001/jama.286.17.2114.

5.Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II Sex, Gender, and Hormones Report. The Ocular Surface. 2017;15(3):284–333. doi:10.1016/j.jtos.2017.04.001.

6.Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. The Ocular Surface. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008.

Published

2026-11-01